UNSPSC 51373003: Pentazocine

This classification denotes an opioid receptor agonist and opioid with the molecular formula C19H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RP4A60D26L, chemically known as 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol but generally known as pentazocine, which bears US NIH Compound Identifier 4736. European Medicines Agency schedules Pentazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09688MIG.

UNSPSC 51373003 Pentazocine is a Commodity code that captures opioid pharmaceutical procurement by state and local health agencies, though recent opportunities show the code tag applied to a broader range of controlled and non-controlled pharmaceuticals, naloxone products, and pharmacy benefit program management. State and local governments buy pentazocine and related pharmaceutical products through their health departments, community health programs, and multistate cooperative purchasing alliances, often bundling opioid procurement with naloxone (opioid reversal agents) and safe drug deactivation systems as part of harm-reduction and community health initiatives. The issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing organizations representing multiple states and municipalities. Procurement structures range from straightforward purchase orders for specific pharmaceutical units to complex manufacturer-tier RFPs establishing statewide or multistate contracts with wholesale distribution networks.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the contract includes a two-year initial term with one-year renewal option and E-Verify compliance requirements. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative fee compliance, EDI capability, and cGMP/DSCSA certification.